University of Tasmania
Browse

File(s) under permanent embargo

Prediction of Individual Genetic Risk to Prostate Cancer Using a Polygenic Score; PRACTICAL consortium

journal contribution
posted on 2023-05-18, 14:00 authored by Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D, Kote-Jarai, Z, Al Olama, AA, Benlloch, S, Muir, K, Giles, GG, Southey, MC, Liesel FitzgeraldLiesel Fitzgerald, Henderson, BE, Schumacher, F, Haiman, CA, Schleutker, J, Wahlfors, T, Tammela, TLJ, Nordestgaard, BG, Key, TJ, Travis, RC, Neal, DE, Donovan, JL, Hamdy, FC, Pharaoh, P, Pashayan, N, Khaw, K-T, Stanford, JL, Thibdoeau, SN, McDonnell, SK, Schaid, DJ, Maier, C, Vogel, W, Luedeke, M, Herkommer, K, Kibel, AS, Cybulski, C, Lubinski, J, Kluzniak, W, Cannon-Albright, L, Brenner, H, Butterbach, K, Stegmaier, C, Park, JY, Sellers, T, Lim, H-Y, Slavov, C, Kaneva, R, Mitev, V, Batra, J, Clements, JA, Spurdle, A, Teixeira, MR, Paulo, P, Maia, S, Pandha, H, Michael, A, Kierzek, A, Gronberg, H, Wiklund, F

BACKGROUND: Polygenic risk scores comprising established susceptibility variants have shown to be informative classifiers for several complex diseases including prostate cancer. For prostate cancer it is unknown if inclusion of genetic markers that have so far not been associated with prostate cancer risk at a genome-wide significant level will improve disease prediction.

METHODS: We built polygenic risk scores in a large training set comprising over 25,000 individuals. Initially 65 established prostate cancer susceptibility variants were selected. After LD pruning additional variants were prioritized based on their association with prostate cancer. Six-fold cross validation was performed to assess genetic risk scores and optimize the number of additional variants to be included. The final model was evaluated in an independent study population including 1,370 cases and 1,239 controls.

RESULTS: The polygenic risk score with 65 established susceptibility variants provided an area under the curve (AUC) of 0.67. Adding an additional 68 novel variants significantly increased the AUC to 0.68 (P = 0.0012) and the net reclassification index with 0.21 (P = 8.5E-08). All novel variants were located in genomic regions established as associated with prostate cancer risk.

CONCLUSIONS: Inclusion of additional genetic variants from established prostate cancer susceptibility regions improves disease prediction.

History

Publication title

The Prostate

Volume

75

Issue

13

Pagination

1467-1474

ISSN

0270-4137

Department/School

Menzies Institute for Medical Research

Publisher

Wiley-Liss

Place of publication

United States

Rights statement

Copyright? 2015 Wiley Periodicals, Inc.

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC